Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
The impact of FADS genetic variants on ?6 polyunsaturated fatty acid metabolism in African Americans.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 Nov; 121(5):1088-94.
View in:
PubMed
subject areas
Adult
Aged
Antibodies, Monoclonal
Crohn Disease
Double-Blind Method
Etanercept
Female
Gastrointestinal Agents
Humans
Immunoglobulin G
Infliximab
Male
Middle Aged
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
authors with profiles
Stephen B. Hanauer